Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Biodelivery Sci Intl (BDSI) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 102,820
  • Shares Outstanding, K 53,640
  • Annual Sales, $ 48,230 K
  • Annual Income, $ -37,670 K
  • 36-Month Beta 1.97
  • Price/Sales 2.13
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +14.53%
on 11/23/16
2.35 -26.89%
on 11/11/16
-0.28 (-14.10%)
since 11/07/16
3-Month
1.50 +14.53%
on 11/23/16
3.00 -42.73%
on 09/28/16
-0.80 (-31.83%)
since 09/07/16
52-Week
1.50 +14.53%
on 11/23/16
5.53 -68.93%
on 12/08/15
-3.57 (-67.52%)
since 12/07/15

Most Recent Stories

More News
BioDelivery Sciences: Can Bunvail and Belbuca's Sales Improve?

On Nov 25, 2016, we issued an updated research report on BioDelivery Sciences International, Inc. (BDSI).

Company News for November 10, 2016

Companies in the News are: BDSI,DISH,EGRX,HCAP

BioDelivery (BDSI) Reports Wider-than-Expected Loss in Q3

BioDelivery Sciences International, Inc. (BDSI) reported a loss of 30 cents per share in the third quarter of 2016, wider than Zacks Consensus Estimate of 26 cents but narrower than the year-ago loss of...

BioDelivery (BDSI) Q3 Loss Wider Than Expected; Revenue Beat

BioDelivery Sciences International, Inc.'s (BDSI) third-quarter 2016 loss of 30 cents per share is wider than consensus estimates of 26 cents per share.

BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2016 Financial Results

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the third quarter ended September 30, 2016, and provided an update on recent business highlights and upcoming...

BioDelivery Sciences to Present at the Stifel 2016 Healthcare Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference. The presentation,...

Will BioDelivery (BDSI) Stock Disappoint in Q3 Earnings?

BioDelivery Sciences International, Inc. (BDSI) is scheduled to report third-quarter 2016 results on Nov 9, before the opening bell.

BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2016 Financial Results on Wednesday, November 9

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host conference call and webcast to report its financial results for the third quarter ended September 30, 2016, on Wednesday,...

BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the addition of BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) as a preferred drug to the Texas Medicaid formulary from its...

BioDelivery Sciences (BDSI) Board Appoints New Members

BioDelivery Sciences International, Inc. (BDSI) announced a couple of changes in its management. Timothy C. Tyson has been appointed to the company???s board of directors as an independent member.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any...

See More

Support & Resistance

2nd Resistance Point 1.98
1st Resistance Point 1.87
Last Price 1.73
1st Support Level 1.67
2nd Support Level 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.